PFD report

Imogen Heap · Prevention of Future Deaths report

Pin Get email alerts Request correction

Issued 8 Nov 2024•Blackpool and the Fylde

Report record

Published report and response evidence

This page connects the concerns raised in this report with statements found in recipients’ published responses. A link shows a clear evidence connection; it does not assign responsibility.

View original report
Concerns
1

Raised in this report

Recipients
1

Named on the report

Responses found
1

Of 1 recipient

Stated actions
2

Described in responses

Source document

Full report text

This is the full text from the original published report.

Open published report

Concerns and recipient responses

Select any concern, action or position to view the source wording.

Report evidence summary

Concerns raised1

  1. Under-appreciation of the risks posed by elevated propranolol medication levels
    Part of recurring concern: Failure to identify clinically significant medication risks
Responses linked to these concerns

Each statement is shown once, even when linked to more than one concern.

Actions described in response An action is something a recipient says it has done, is doing, or plans to do in response to a concern raised.1

  1. Action

    Complete a surveillance review of current evidence and discuss the findings with GP advisors regarding propranolol guidance.

    Stated by National Institute for Health and Care ExcellenceStated completedThe respondent said that this action was complete when they made their response on 13 November 2024.

Respondent positions A position is what a recipient says about a concern when it does not describe a specific action.1

  1. Position

    The guideline will not be updated at this time because MHRA found no need for a safety communication and noted widespread safe propranolol use.

    Stated by National Institute for Health and Care ExcellenceNo action considered necessaryThe respondent said that no further action was needed.

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Under-appreciation of the risks posed by elevated propranolol medication levels

Wider context from the report

“My concern is that Propranolol continues to be a drug which is widely prescribed, and often to young people reporting symptoms of anxiety, but that there continues to be an under-appreciation of the level of risk posed by an elevated level of propranolol medication can be. ”

Is this part of a recurring concern?

Yes — Failure to identify clinically significant medication risks.

Open source report

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Complete a surveillance review of current evidence and discuss the findings with GP advisors regarding propranolol guidance.

Verbatim wording from the response

“We also outlined that our guidance surveillance team would review any current evidence and consult with topic experts to consider whether an update to CG113 was required, we have now had a surveillance review and discussed with our GP advisors.”

Source location

Update from NICE 10 June 2025
Page 1 · response
Published 13 November 2024

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

The guideline will not be updated at this time because MHRA found no need for a safety communication and noted widespread safe propranolol use.

Verbatim wording from the response

“The Medicines & Healthcare products Regulatory Agency (MHRA) have told us that they will not be issuing a drug safety update (DSU) for propranolol. The MHRA stated that ‘The issue of whether or not a DSU was warranted was considered within MHRA in Autumn 2024 and then discussed at one of the monthly DSU planning meetings where a decision was taken not to issue a safety communication. One of the concerns with any communication was inadvertently raising the profile of propranolol overdose. A couple of factors which were taken into consideration are that (i) quite a lot of overdoses with propranolol are mixed overdoses of more than one drug, and that (ii) propranolol is used very widely with millions of items prescribed and used safely each year’. Therefore, our conclusion is that we will not be updating CG113 at this time.”

Source location

Update from NICE 10 June 2025
Page 1 · response
Published 13 November 2024

Open published response

Other statements in published responses

These actions and other statements could not be clearly connected to one concern in this report.

Recipient-stated actions An action is something a recipient says it has done, is doing, or plans to do in response to a concern raised.1

  1. 1

    Review evidence and consult topic experts to consider updating CG113 with a specific recommendation on propranolol for generalised anxiety disorder.

    Stated by National Institute for Health and Care ExcellenceStated plannedThe respondent said that this action was planned when they made their response on 13 November 2024.

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Review evidence and consult topic experts to consider updating CG113 with a specific recommendation on propranolol for generalised anxiety disorder.

Verbatim wording from the response

“In response to your report we will review the evidence and consult with topic experts to consider an update to CG113 to make a specific recommendation on whether propranolol should be an option in the treatment pathway for people with generalised anxiety disorder.”

Source location

Response from NICE
Page 1 · response
Published 13 November 2024

Open published response
Back to top

Information checked against the published report and official responses · Data reviewed 7 Sep 2026 · About data quality and limitations

Official responses located
1/1

Data last updated 7 September 2026